Sigma-Aldrich Corporation (SIAL) announced that its biologics and early-development services unit -- BioReliance -- has introduced the updated Big Blue Mouse Transgenic Rodent Mutation (:TRM) assay. The assay is qualified to meet the new Organization for Economic Co-Operation and Development (:OECD) Test Guideline 488 requirements for evaluation of in vivo mutagenicity.
Big Blue assay meets the requirements of OECD Test Guideline 488 as well as additional regulatory guidelines and has been recommended by various agencies and expert groups, including the European Chemicals Agency, as an accepted assay for evaluating mutagenicity in somatic and male germ cell tissues.
The assay service matches BioReliance’s existing portfolio of comprehensive genotoxicity testing methods and also offers a unique confirmatory test for drugs and chemicals that initially test positive for in vitro mutation assays.
Recently, Sigma-Aldrich’s biological products and services business – Sigma Life Science – launched a novel editing tool Sigma CRISPRs. CRISPRs are a mammalian genome editing tool appropriate for screening and exploratory studies. They are inexpensive tools that can be used for the development of targeted gene editing.
Sigma-Aldrich released its second quarter 2013 results in July. The company posted adjusted earnings of $1.05 per share, above the year-ago earnings of 97 cents. The results also beat the Zacks Consensus Estimate of $1.03. The adjusted earnings exclude other charges of 7 cents a share.
Profit as reported, rose roughly 3.5% year over year to $119 million (or 98 cents per share) in the quarter from $115 million (or 94 cents per share) a year ago.
Net sales increased 3% year over year to $681 million in the reported quarter, surpassing the Zacks Consensus Estimate of $679 million. Organic sales growth in the quarter was 4%, while foreign exchange translation had a negative impact of 1%.
Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).
Other companies in the specialty chemical space with favorable Zacks Rank are Ferro Corp. (FOE), Minerals Technologies Inc. (MTX) and Sensient Technologies Corp. (SXT). While Ferro carries a Zacks Rank #1 (Strong Buy), Minerals Technologies and Sensient Technologies retain a Zacks Rank #2 (Buy).
More From Zacks.com